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DObjectives: In destructive aortic valve endocarditis with abscess formation in the root, homografts are used
more often than xenografts. Because we had reliable perioperative results with Freestyle (Medtronic Inc,
Minneapolis, Minn) xenograft root replacement in these complex patients, we analyzed the long-term outcome
in this high-risk indication.
Methods: Of 126 consecutive patients with aortic valve endocarditis treated by surgery from 1997 to 2012, 32
(25.4%) received a Freestyle aortic root replacement for severe, destructive valve endocarditis and were studied
retrospectively with approval of the local ethical committee. Perioperative complications, recurrence of endo-
carditis, and long-termmorbidity andmortality were analyzed. The follow-up period was 3months to 11.5 years.
Results: Indication for surgery was native (n ¼ 9) and prosthetic valve endocarditis (n ¼ 23). In 18 patients,
concomitant procedures were performed: coronary bypass (n¼ 9), additional valve surgery (n¼ 6), and ascend-
ing aortic surgery (n¼ 7). Thirty-day mortality was 19.4% (n¼ 6). There were no instances of technical failure
requiring modification of the surgical strategy or reoperation for anastomotic bleeding. Actuarial survival at 5
and 10 years was 61.9% and 54.2%, respectively. Freedom from death, reoperation for prostheses dysfunction,
and recurrence of endocarditis as the composite end point at 5 and 10 years was 56.3% and 53.1%, respectively.
Conclusions: The Freestyle root was used successfully with no technical complications in all patients with
most severe destructive aortic root endocarditis. In view of this complex patient population, short- and
long-term results make this conduit a reliable choice for treatment of this condition. (J Thorac Cardiovasc
Surg 2014;147:1265-70)Surgery for severe infective endocarditis (IE) is still chal-
lenging and associated with significant morbidity and
mortality.1 The choice of the optimum conduit for aortic
root replacement in destructive endocarditis with annular,
supra-annular, or infra-annular abscess formation depends
on technical considerations, graft resistance to infection,
and durability of the graft. Homografts, pericardial patch re-
pair with prosthetic valve replacement, prosthetic valved
conduits, and xenografts may be used.
According to American College of Cardiology/Ameri-
can Heart Association guidelines, an aortic homograft is
considered the gold standard, and especially aortic valve
re-replacement in patients with active prosthetic valve endo-
carditis (PVE) is recommended to be performed with a ho-
mograft (class of recommendation IIa, level of evidence
C).1 In contrast, European Society of Cardiology guidelines
advise valve replacement in aortic valve IE by a mechanicale Department of Heart Surgery, Medical University Innsbruck, Innsbruck,
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ilized homografts is not recommended explicitly but
might reduce the risk of persistent or recurrent infection.
However, mechanical prostheses and xenografts compare
favorably with the advantage of improved durability.
Homografts or stentless xenografts are considered com-
parable and may be preferred in PVE or in cases where
there is extensive aortic root destruction with aortoven-
tricular discontinuity.2
Because of promising results in smaller series3-5 and the
lack of long-term studies, we aimed to investigate perioper-
ative complications caused by technical problems inherent
to the graft, recurrence of endocarditis, and long-term
outcome in patients who had a Freestyle (Medtronic Inc,
Minneapolis, Minn) xenograft root implantation for severe
excavating aortic valve endocarditis.MATERIALS AND METHODS
Patients
A total of 126 consecutive patients with a diagnosis of acute valve en-
docarditis were treated by surgery from 1997 to 2012 at our department.
Of these, 32 patients (25.4%) with most severe destructive aortic root en-
docarditis had Freestyle xenograft full root replacement between 1997 and
2012 constitute the population of this study. The study was approved by the
local ethical committee, and individual patients’ informed consents were
obtained.
IE was diagnosed according to modified Duke Criteria6 based on
clinical signs, blood culture, histologic, examination, and transesophagealdiovascular Surgery c Volume 147, Number 4 1265
Abbreviations and Acronyms
EF ¼ ejection fraction
IE ¼ infective endocarditis
LVOT ¼ left ventricular outflow tract
NVE ¼ native valve endocarditis
PVE ¼ prosthetic valve endocarditis
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Dechocardiography. Indication for surgery in these patients was based on the
transesophageal echocardiography results of root abscess or intracardiac
fistula formation. Severe excavating aortic valve endocarditis was defined
by intraoperative findings of acute necrotizing endocarditis with vegeta-
tions and partial or total destruction of the annulus and left ventricular
outflow tract (LVOT).
Identification of the infective germ was done from cultures of blood or
surgical specimens. Patients were treated with appropriate antibiotics be-
fore and after operation.
Native valve endocarditis (NVE) with abscess or fistula formation was
present in 9 patients, and 23 patients underwent operation for PVE with an-
nulus destruction. The previous procedure in these cases had been an aortic
valve replacement with 13 biological prostheses, 9 mechanical valve pros-
theses, and 1 homograft valve. Additional procedures had been ascending
aorta replacement (n ¼ 3), ascending aorta reduction plasty (n ¼ 2), coro-
nary artery bypass grafting (n ¼ 4), and mitral valve repair or replacement
(n ¼ 2). Nineteen patients had 1 previous aortic valve surgery, 3 patients
had 2 previous aortic valve surgeries, and 1 patient had 4 previous aortic
valve surgeries. The prior procedures had been performed 27 days to 36
years (median, 5.5 years) before Freestyle root replacement. Six patients
had a history of cerebrovascular events that had occurred between 1 day
and 8 years (median, 1.5 years) before; 4 events were a septic embolism re-
lated to IE.
Technical success of surgery (successful reconstruction of the aortic
root and LVOTwithout need for early reoperation), perioperative compli-
cations (eg, mortality and early recurrence of endocarditis), and long-term
outcome regarding survival, late PVE, relapse or reinfection, and late pros-
thesis dysfunction due to degeneration needing reoperation were analyzed.
Perioperative mortality was defined as mortality within 30 days or dur-
ing hospital stay. Late mortality was defined as death thereafter. Follow-up
period was 3 to 150 months (median, 20 months) and 100% complete, in-
cluding clinical and echocardiographic examinations. The standard sched-
ule was to follow up the patients yearly at our cardiology department,
including transthoracic echocardiography. Few patients were examined
by their local physicians, and the results were sent to us. In any case, at least
1 recent follow-up (<3-6 months) was required.
Surgical Technique
Mild hypothermic cardiopulmonary bypass (32C) was established us-
ing bicaval and ascending aortic cannulation. Myocardial protection was
accomplished by retrograde (coronary sinus) and, if feasible, antegrade
(by intubation of the coronary ostia) blood cardioplegia and topical cool-
ing. Delivery of retrograde cardioplegia was repeated every 20 to 25 min-
utes. Complete transection of the aorta was performed after preliminary
evaluation of the extent and severity of the disease, and radical resection
of all infected and necrotic tissue was donewithout consideration of the ex-
tent of the created defect and later reconstruction or creation of heart block.
Typically, the full extent of the destructive process became evident only
after radical debridement. Specimens of the valve and necrotic material
were sent for bacteriologic and histopathologic investigation. Reconstruc-
tion of the LVOTand aortic root was accomplished by means of a Freestyle
xenograft aortic root. Because the aortic annulus was invariably destroyed
by the inflammatory process, full root replacement with reimplantation of1266 The Journal of Thoracic and Cardiovascular Surthe coronary ostia using the button technique had to be performed. The
graft was sutured to the LVOTwith interrupted or running 4-0 Prolene su-
tures or a combination of both depending on the surgeon’s preference and
the individual situation. Interrupted sutures were usually tied over a strip of
pericardium to prevent leakage. In 6 cases, a patch of pericardium had to be
used to repair the LVOTat the level of the aorto-mitral curtain, and then the
xenograft was sutured to the pericardium; 5-0 Prolene running sutures were
used for implantation of the coronary buttons. For the distal anastomosis
between the xenograft and the ascending aorta, a 4-0 Prolene running su-
ture was used, which in all but the initial cases was buttressed by a strip
of pericardium to prevent bleeding from the xenograft. Intracardiac defects
also were closed with pericardium. Generally, 0.5% glutaraldehyde fixed
autologous or bovine pericardium was used. The same material was used
to repair defects of the mitral valve leaflets if present. Additional replace-
ment of the ascending aorta with a homograft or Dacron aortic prosthesis
was necessary in 3 patients.Statistical Analysis
Continuous variables were expressed as median and range or mean 
standard deviation, and categoric variables were expressed as percentages.
Differences of categoric variables were calculated with the Fisher exact
test, estimates of survival and incidence of valve-related complications
were calculated using the Kaplan–Meier or log-rank method, and differ-
ences in continuous variables were calculated with the Student t test.
Statistical analysis was performed using SPSS version 18.0 (SPSS, Inc,
Chicago, Ill).RESULTS
Thirty-two patients received a Freestyle xenograft aortic
root replacement with or without additional procedures; 22
patients were men (68.8%), and 10 were women. The me-
dian age was 61 years (range, 16-79 years). Demographics
and preoperative risk factors are shown in Table 1.
Mean bypass (cardiopulmonary bypass) time was 283 
84 minutes, and mean crossclamping (aortic crossclamp)
time was 172  40 minutes. In 9 patients, hypothermic cir-
culatory arrest was required for 5  11 minutes. Replace-
ment of the ascending aorta due to type A dissection was
required in 1 patient, and the necessary re-replacement of
the ascending aorta was performed with an open distal anas-
tomosis with antegrade brain perfusion in 1 patient. In 7 pa-
tients, repeated short episodes of hypothermic circulatory
arrest were required for control of bleeding during dissec-
tion or after release of the aortic clamp. Median intensive
care unit stay was 5 days (range, 1-136 days), median ven-
tilation time was 2 days (range, 1-115 days), and hospital
stay was 26 days (range, 21-136 days).
The xenografts implanted in 32 patients ranged from 21
to 29 mm in size: 21 mm in 4 patients, 23 mm in 13 patients,
25 mm in 8 patients, 27 mm in 6 patients, and 29 mm in 1
patient. Eighteen patients (56.3%) had concomitant surgi-
cal procedures: coronary artery bypass grafting (n¼ 9), mi-
tral valve replacement or repair (n ¼ 3), tricuspid valve
repair (n ¼ 2), pulmonary valve replacement (n ¼ 1),
LVOT patch repair (n ¼ 6), ascending aorta replacement
(n ¼ 3), and ascending aorta reduction plasty (n ¼ 4)
(Table 2).gery c April 2014
TABLE 1. Patient demographics
n 32
Age (y, mean  SD) 58.5  15.3
Male sex (n) 22
Arterial hypertension (n) 21
Preoperative positive blood cultures (n) 13
EF (%, mean  SD) 49.1  11.6
Preoperative renal failure with hemofiltration/dialysis (n) 6
History of cerebrovascular accident (n) 7
Previous cardiac operation (n) 23
Active endocarditis (n) 32
Abscess/fistula (n) 29
EF, Ejection fraction; SD, standard deviation.
TABLE 2. Concomitant procedure
n 32
Coronary artery bypass graft (n) 9
Mitral valve surgery (n) 3
Tricuspid valve surgery (n) 2
Pulmonary valve surgery (n) 1
LVOT patch repair (n) 6
Ascending aortic replacement (n) 3
Ascending aortic reduction plasty (n) 4
LVOT, Left ventricular outflow tract.
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DMicrobiological testing was positive in 13 blood samples
or cultures of the resected valves. No molecular biological
investigations of specimens were performed. The most fre-
quent germwas Staphylococcus aureus (n¼ 7), followed by
Staphylococcus epidermidis (n ¼ 1), Enterococcus faecalis
(n ¼ 3), Aspergillus (n ¼ 1), and Klebsiella pneumonia
(n¼ 1). Blood cultures and valves remained sterile in 13 pa-
tients, and the result was unknown in 6 patients. Every pa-
tient was treated with antibiotics according to sensitivity
testing or broad spectrum antibiotics, if therapy was em-
piric. A second- or third-generation cephalosporin, amino-
glycoside, and in most cases metronidazole were used in
most cases. The antibiotic therapy was started on the day
of diagnosis and continued for 3 to 6 weeks after surgery
consistent with recent European Society of Cardiology
Guidelines (2) (NVE 2-6 weeks, PVE>6 weeks).FIGURE 1. Actuarial survival after Freestyle root replacement for root
endocarditis.Complications
Perioperative mortality was 18.8% (n ¼ 6) and not sig-
nificantly different in patients undergoing operation for
PVE (5/23) or NVE (1/9) (P ¼ .648). Between postopera-
tive days 1 and 5, these patients died of multiorgan failure
(n ¼ 2), cardiac decompensation (n ¼ 1), ischemic heart
failure (n¼ 1), or acute cardiac death (n¼ 2). Although aor-
tic crossclamp timewas not different between survivors and
nonsurvivors (mean 176  42 vs 163  38 minutes,
P ¼ .806), cardiopulmonary bypass time showed a signifi-
cant difference between the 2 groups (mean 268  74 vs
351  98 minutes, P ¼ .027).
Three patients (9.4%) required reoperation for bleeding
due to coagulopathy; 2 patients had 1 reoperation and 1 pa-
tient had 4 reoperations. However, no anastomotic bleeding
at the site of the xenograft was detectable, and no complica-
tion related to the Freestyle prosthesis was found. Three
patients required postoperative mechanical circulatory sup-
port (9.3%, 2 of them died), 2 with an intra-aortic balloon
pump and 1 by extracorporeal membrane oxygenation; 3
patients (9.3%) received a permanent pacemaker for new
heart block; 6 patients (18.8%) required temporary hemo-
filtration for new-onset acute renal failure; and 2 otherThe Journal of Thoracic and Carpatients were already on preoperative long-term hemodial-
ysis for chronic renal failure. There were no instances of
early xenograft failure requiring reoperation and replace-
ment of the xenograft in the postoperative period.
Thromboembolic Events
One patient had ischemic stroke caused by multiple em-
bolic lesions of different age. These lesions were detected
with a cerebral magnetic resonance tomography 14 days af-
ter surgery initiated by clinical symptoms. The patient pre-
sented with decreased motor function of the left arm and
both legs. Follow-up after 3 months with a control magnetic
resonance tomography showed declining cerebral findings.
He gained full recovery of his motor function within 8
months with no gross neurologic residue.
Long-Term Results
Actuarial survival at 10 years was 54.2% (Figure 1) and
did not differ for PVE (56.5%) and NVE (55.5%)
(P ¼ .506). Total observed late mortality was 25% (n ¼ 8).
These patients died on days 94, 106, and 153, and after 1.1,
3.4, 6, 10.5, and 11 years as a result of acute myocardial
infarction (n¼ 1), unexplained sudden death (n¼ 2), cardiac
decompensation (n ¼ 2), brainstem infarction (n ¼ 1),
Staphylococcus sepsis (n ¼ 1), and unknown reasons
(n ¼ 1), respectively.diovascular Surgery c Volume 147, Number 4 1267
Acquired Cardiovascular Disease Heinz et al
A
C
DValve-Related Events
During follow-up, 3 patients underwent reoperation: 1
after 3 years and 1 after 12 years for xenograft degeneration
(n ¼ 2, 6.3%) and 1 after 3 years for recurrent endocarditis
(n ¼ 1, 3.1%). E faecalis had been cultivated at the initial
procedure for PVE; at reoperation, blood cultures and the
explanted xenograft remained sterile. The xenograft was re-
placed by a mechanical composite graft (Valsalva 21 mm;
St Jude Medical Inc, St Paul, Minn), and additional venous
coronary bypass grafting was performed to the left anterior
descending, obtuse marginal, and right coronary arteries.
Because no germ could be cultivated, it remains unclear
whether a relapse or re-IE occurred in this case. From the
clinical, macroscopic, and histologic aspect, however, there
was no doubt that IE was present. In the 2 other cases, the
xenograft was degenerated with severe calcific stenosis and
replaced by a mechanical conduit (St Jude Medical 21 mm
[St Jude Medical Inc] and Carbo-Seal 21 mm [Sorin SpA,
Milan, Italy]) by the Bentall procedure. The explanted xe-
nografts remained sterile. One of the latter cases with PVE
at the previous procedure but not at reoperation required
additional pericardial patch repair of the LVOT and right
pulmonary artery because of concretion of the Freestyle
xenograft with the pulmonary artery. In the other patient,
in whom the initial procedure was performed for NVE,
a single coronary bypass graft to the right coronary artery
was necessary.
Echocardiographic results (transthoracic echocardiogra-
phy) during follow-up (ranging from 1.8 to 153 months
after surgery) showed good cardiac function with a median
ejection fraction (EF) of approximately 57% (30%-82%).
The median left ventricular end-diastolic diameter was
51.8 7.7 cm, and the mean transprosthetic Doppler gradi-
ent was 8.5  4.9 mm Hg. EF remained stable or even
improved up to 30% in 24 patients 3 months to 1 year after
surgery. In 2 patients, a mild reduction of the postoperative
EF was found.Event-Free Survival
To evaluate the efficacy of treatment, a composite end
point at 30 days of mortality, reoperation for bleeding,
and thromboembolic events, and a composite end point of
mortality, reoperation for prostheses dysfunction, and re-
currence of endocarditis at 5 and 10 years were defined to
investigate freedom from treatment failure. Actuarial free-
dom from events at 30 days was 68.75%, and freedom
from events at 5 and 10 years was 56.3% and 53.1%,
respectively.DISCUSSION
In this study we aimed to evaluate the comparability of
xenograft with homograft root replacement in patients
with severe destructive aortic root endocarditis in respect1268 The Journal of Thoracic and Cardiovascular Surto intraoperative technical complications and long-term
outcome.
The present study exclusively included patients with
acute IE with extensive root destruction, and only Freestyle
root replacements were performed. Additional procedures
were performed in more than 50% of cases. Our results
show that therewere no instances of technical failure requir-
ing modification of the surgical strategy or reoperations for
anastomotic bleeding. The perioperative survival and free-
dom from events at 30 days, 5 years, and 10 years were
acceptable for this severely ill population.
The 20-year experience of a German group studying ho-
mograft aortic root replacement in IE shows results similar
to our findings with xenografts concerning 30-day survival
(83.8% vs 81.2%), recurrence of endocarditis (5.4% vs
3.1%), and valve deterioration (8.6% vs 6.3%) during
follow-up.7 El-Hamamsy and colleagues8 found that the
use of the porcine xenograft root is associated with a signif-
icantly lower rate of structural valve deterioration and reop-
eration compared with homograft root replacement. Miceli
and colleagues9 currently presented low early and mid-term
mortality, good hemodynamic performance, low rates of
valve-related morbidity, and low recurrent infection, espe-
cially in case of PVE, in an 18-patient series with 24 months
of follow-up.
The advantages of homografts and stentless xenografts are
well known. On the one hand, aortic root homografts have
been used for several decadeswith good long-term results.7,10
In comparison with the more obstructive valve prostheses,
their lower transvalvular gradients are associated with
better left ventricular mass regression.11 Homografts
show good resistance to infection, and other valve-related
complications are rare.12 Limited homograft availability
determines that they are not used routinely.13 Because of
low-grade immunologic mechanisms, homografts can un-
dergo late degeneration marked by severe calcification
and valve dysfunction.8 On the other hand, there is the
Freestyle xenograft, which is treated with alpha-oleic
acid as an attempt to reduce long-term valve degenera-
tion.8,14 Freestyle valves are readily available in different
sizes (19-29 mm)8 and storable for even unscheduled use.
Although xenograft root replacement may be associated
with higher surgical morbidity and mortality because of
prolonged myocardial ischemia and more perioperative
bleeding complications,15 several clinical studies have
demonstrated excellent performance.
Recent studies by the Freestyle Valve Study Group have
demonstrated the full root implantation of the xenograft to
be associated with a superior hemodynamic performance
in the long-term follow-up compared with homografts.16,17
In a comparison of stentless and stented valves, Funder18
stated that these prostheses perform similarly in regard to
various clinical parameters and valve-related mortality,
but stentless valves have several advantages concerninggery c April 2014
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domized trial, Lehmann and colleagues19 showed a signifi-
cantly higher long-term survival in stentless compared with
stented valve replacement (78% and 66%, respectively) in
223 patients.
Overall excellent hemodynamic results with low gradi-
ents at acceptable operative risk can be achieved by full-
root stentless valve replacement.20 By comparing our
10-year survival of 54.2% with the study of Lehmann
and colleagues19 with an 8-year survival of 78%, it must
be considered that our patient population underwent oper-
ation for excavating aortic root endocarditis only, and in
71.9% of the cases it was performed as a reoperation
with 1 to 4 previous valve surgeries.
In a retrospective study on valve replacement in 77 pa-
tients with acute IE, Delay and colleagues21 showed that
prosthetic valve replacement for NVE resulted in excellent
long-term survival without reoperation in both the aortic
and mitral positions. For PVE, the 5-year total survival
and survival without reoperation were 59% and 40%, re-
spectively. This outcome of PVE demonstrates a significant
difference compared with patients undergoing surgery for
NVE.21 Further studies also indicate PVE is an independent
risk factor for perioperative mortality22,23 and limited long-
term survival.23,24 In contrast to these studies using mainly
mechanical or biological valved conduits, our results show
excellent xenograft function up to 11 years, with no
significant difference between PVE and NVE.
Recurrence of endocarditis in our patients was low
(3.1%) because of aggressive antibiotic therapy (long dura-
tion and number of antibiotics). The result is consistent with
that of a French study showing that adequate antimicrobial
therapy in IE significantly improves prognosis.25With these
findings, it is questionable if the use of a homograft reduces
the risk of persistent or recurrent infection compared with
a xenograft or if both conduits are likewise effective.Study Limitations
This was a retrospective study design with no control
group. Although it is the largest published series on the
use of the Freestyle in this indication, the number of patients
is still small but comparable to published series on the use of
homografts.CONCLUSIONS
To date, this is the largest reported series of patients with
most severe destructive aortic root endocarditis who had re-
pair of the LVOTand aortic root using the Freestyle porcine
aortic root. In view of this complex patient population,
short- and long-term results make this conduit a reliable
choice for treatment of this condition. The xenograft can
be used successfully instead of a homograft with compara-
ble or even better long-term durability.The Journal of Thoracic and CarReferences
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